Celldex Therapeutics Announces Upcoming Presentation at Lazard Capital Markets Healthcare Conference

Celldex Therapeutics Announces Upcoming Presentation at Lazard Capital Markets Healthcare Conference

Celldex Therapeutics, Inc.Sarah Cavanaugh, 781-433-3161Vice President of IR & Corp CommorBMC CommunicationsBrad Miles, 646-513-3125

(NASDAQ: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 9:30 am ET at The Pierre Hotel in New York City.

A of the presentation will be available online on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay of the presentation will be available for 30 days following the event.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit .

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.